Market News & Trends
OrphAI Therapeutics Receives Orphan Drug Designation for AIT-101 as a Treatment for Amyotrophic Lateral Sclerosis in the European Union
OrphAI Therapeutics Inc. recently announced it has received Orphan Drug Designation (ODD) in the European Union (EU) for the treatment of amyotrophic lateral sclerosis (ALS).…
Alvotech Announces Expected Global Market Entry Dates for Biosimilar to Stelara
Alvotech recently announced it has reached settlement agreements with Johnson & Johnson in Japan, Canada, and in the European Economic Area (EEA) for AVT04, a…
Selkirk Pharma Announces New APS Qualified Facility With Advanced Fill/Finish Capacity in Spokane, WA
Selkirk Pharma, Inc. recently announced the Aseptic Process Simulation (APS) qualification of its sterile manufacturing facility and newly available fill/finish capacity. This development marks a…
Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published
Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys…..
Petros Pharmaceuticals Enters AI Licensing Agreement With Leading Multi-Billion-Dollar Software Provider
Petros Pharmaceuticals, Inc. recently announced a new partnership with a leading, multi-billion-dollar AI software provider to adapt its technology for self-screening and other benefits as…
FOXO Technologies Announces Non-Binding Agreement for Potentially Transformative Merger With M2i Global
FOXO Technologies Inc. recently announced it has entered into a non-binding agreement for a proposed merger with M2i Global, Inc., which specializes in the development…
PathAI Announces Exclusive Collaboration With Roche Tissue Diagnostics to Advance AI-enabled Interpretation for Companion Diagnostics
PathAI, Inc. recently announced an expanded and exclusive relationship with Roche Tissue Diagnostics (RTD) that will bring AI-enabled interpretation to companion diagnostics. Building upon the success…
VantAI Enters $674-Million Collaboration With Bristol Myers Squibb to Accelerate Molecular Glue Drug Discovery Through Artificial Intelligence
Collaboration to leverage VantAI’s expertise in generative AI and geometric deep learning to identify molecular glues against targets of interest with an option to expand to additional programs….
TILT Biotherapeutics Awarded Grant from US Department of Defense for Ovarian Cancer Immunotherapy Research
TILT Biotherapeutics recently announced it has been selected by the US Department of Defense (DOD), America’s largest government agency, to receive a $2-million grant for…
Silo Pharma’s Ketamine Implant Demonstrates Successful Drug Delivery
Silo Pharma, Inc. recently provided a positive update on SP-26, its novel time-released, dose-controlled formulation of ketamine initially targeted for fibromyalgia. A preclinical research study…
Vetter Contributes to Commercial Launches of Eight Customer Products in 2023
New molecules candidates brought to Vetter in the clinic receive strategic counsel and experienced support to guide their path to market and beyond….
Aptar CSP Technologies Collaborates With ProAmpac to Launch New Active Material Science Packaging Solution
High-performance, moisture-adsorbing flexible packaging powered by Activ-Polymer™ technology delivers simple, fully integrated protection for moisture-sensitive products….
Study Demonstrates the Potential of HelixBind’s RaPID/BSI Assay to Accurately Identify Bloodstream Infections Associated With Sepsis in Patients Undergoing Antimicrobial Treatment
HelixBind, Inc. recently announced the publication of a peer-reviewed study demonstrating the capability of the company’s RaPID/BSI assay to accurately identify bloodstream infections associated with…
NovelMed's Ruxoprubart Receives FDA Orphan Drug Designation for Paroxysmal Nocturnal Hemoglobinuria Treatment
NovelMed recently announced the US FDA has granted Orphan Drug Designation (ODD) to Ruxoprubart, an alternative pathway (AP) blocker anti-Bb antibody, for the treatment of…
Abzena Launches LabZient™, an Analytical Platform to Expedite the Path to IND for Antibodies
Abzena recently announced the launch of its new analytical platform, LabZient™. The standardized and automated platform streamlines the assessment and validation of large molecules, which significantly….
CDMO Alcami Expands Fill/Finish Manufacturing Capacity With New Charleston Line
Alcami Corporation recently announced the strategic expansion of its sterile fill/finish manufacturing capacity with the addition of a new sterile fill/finish line with isolator and two lyophilizers at….
Saghmos Therapeutics Announces Notice of Allowance for Second US Patent for Phase 3-Ready Cardiorenal Metabolic Modulator
Saghmos Therapeutics, Inc. recently announced a Notice of Allowance for a second US patent for its Phase 3-ready product, ST-62516 (trimetazidine), a cardiorenal metabolic modulator.…
Anima Biotech Announces Preclinical Data of Candidate in Idiopathic Pulmonary Fibrosis
Anima Biotech recently announced positive preclinical data of its lung fibrosis candidate. This drug operates through a novel mRNA biology mechanism of action, opening new…
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
Immix Biopharma, Inc. recently announced the European Commission (EC) has granted orphan drug designation to NXC-201 for the treatment of….
FundaMental Pharma GmbH Announces Groundbreaking Proof-of-Concept Study Using a TwinF Interface Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis
FundaMental Pharma GmbH recently announced the publication of a groundbreaking study by Neurobiologists in Heidelberg using FundaMental Pharma’s small molecule TwinF interface inhibitor, FP802…..
